For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development (including 27 and 32,128 for a related party) | 30,753 | |||
| General and administrative (including 322 and 230 for a related party) | 15,399 | |||
| Total operating expenses | 46,152 | |||
| Loss from operations | -46,152 | |||
| Change in fair value of tranche liability (including 331 and 19,064 for a related party) | 365 | |||
| Change in fair value of derivative liabilities (including 1,165 and 2,039 for a related party) | 1,229 | |||
| Interest expense (including 1,384 and 2,656 for a related party) | 1,443 | |||
| Loss on extinguishment and on issuance of convertible promissory notes (including 169 and 34,692 for a related party) | -186 | |||
| Other income, net | 2,749 | |||
| Total other income (expense), net | 2,714 | |||
| Net loss | -43,438 | |||
| Unrealized gain on marketable securities, net of tax | 6 | |||
| Total other comprehensive income | 6 | |||
| Comprehensive loss | -43,432 | |||
| Basic EPS | -2.85 | |||
| Diluted EPS | -2.85 | |||
| Basic Average Shares | 15,267,817 | |||
| Diluted Average Shares | 15,267,817 | |||
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)